Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Pass Above Two Hundred Day Moving Average - Should You Sell?

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX - Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.68 and traded as high as $1.24. Lexicon Pharmaceuticals shares last traded at $1.20, with a volume of 3,914,024 shares.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $4.00 price target on shares of Lexicon Pharmaceuticals in a research note on Tuesday, June 24th. Wall Street Zen began coverage on Lexicon Pharmaceuticals in a research note on Monday, April 21st. They issued a "sell" rating for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $3.67.

Lexicon Pharmaceuticals Trading Down 2.2%

The company has a market capitalization of $399.45 million, a price-to-earnings ratio of -2.17 and a beta of 1.13. The business has a fifty day moving average price of $0.85 and a 200 day moving average price of $0.69. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.22 and a quick ratio of 2.22.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.07) EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 103.16% and a negative net margin of 568.04%. The business had revenue of $1.26 million during the quarter, compared to analyst estimates of $1.26 million. On average, equities analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Lexicon Pharmaceuticals by 77.8% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 65,330 shares of the biopharmaceutical company's stock worth $62,000 after purchasing an additional 28,594 shares during the last quarter. Compagnie Lombard Odier SCmA boosted its holdings in Lexicon Pharmaceuticals by 200.0% during the second quarter. Compagnie Lombard Odier SCmA now owns 330,000 shares of the biopharmaceutical company's stock worth $312,000 after buying an additional 220,000 shares during the last quarter. Acadian Asset Management LLC bought a new position in Lexicon Pharmaceuticals during the first quarter worth about $263,000. AQR Capital Management LLC bought a new position in Lexicon Pharmaceuticals during the first quarter worth about $541,000. Finally, Ieq Capital LLC bought a new position in Lexicon Pharmaceuticals during the first quarter worth about $82,000. Institutional investors own 74.70% of the company's stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.